News

CT011 is an autologous GPC3 CAR T-cell product candidate for the treatment of hepatocellular carcinoma (HCC). CT011 received IND clearance from the NMPA in 2019 for the treatment of patients with GPC3-positive solid tumor which was China’s first IND clearance for CAR T-cell therapy against solid ...Read more »

A Russian university professor in his late seventies suffers from advanced multiple myeloma. After undergoing multiple treatments and two recurrences of autologous transplantation, he learned about the cutting-edge anti-cancer therapy CAR-T in China, so he came to China to receive CAR-T cell ther...Read more »

On July 20th,the New Drug Application (NDA) of pCAR-19B independently developed by Precision Biology was officially accepted by China National Medical Products Administration (NMPA).This product is the first CAR-T product for childhood leukemia in China, which is used to treat patients aged 3-21 ...Read more »

satricabtagene autoleucel（Satri-cel,CT041) is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be first-in-class globally. Satri-cel targets Claudin18.2 positive solid tumors with a primary focus on gastric cancer/gastroesophageal junction canc...Read more »

On September 6, 2021,JW Therapeutics announced that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (relma-cel) ...Read more »

Equecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (R/RMM). On June 30,2023,China’s National Medical Products Admi...Read more »

On October 11, 2024,China’s National Medical Product Administration (NMPA) has approved  Investigational New Drug（IND）application for Inaticabtagene Autoleucel (CNCT19 Injection), a CD19-targeted autologous chimeric antigen receptor (CAR)-T cell therapy, to treat  Immune thrombocytopenia ...Read more »

On March 1st, 2024, China National Medical Products Administration (NMPA) approved the launch of CAR-T cell product Zevorcabtagene AutoLeucel (Zevor-cel, CT053) for the treatment of adult patients with relapsed or refractory multiple myeloma who had progressed after at least 3 lines of treatment(...Read more »

       Clustered regularly interspaced short palindromic repeats (CRISPR) is a third-generation genome editing technique that has revolutionized the world with its high-throughput results. It has been used to treat various biological diseases and infections. Various bacteria a...Read more »

Case 1: The 69-year-old male patient went to the hospital for examination due to chest pain. Unfortunately, he suffered from low-differentiated squamous cell carcinoma of the right upper lung. The patient could not tolerate surgery. After expert consultation, cryoablation was the best solution an...Read more »

Cryoablation: “Good news” for patients with solid tumors in various parts of trunk Famous Hong Kong film star Wu MengDa died of liver cancer, Uncle Da’s departure has caused many people to regret. “Liver cancer” was once known as the king of cancer, and 70% of liver ...Read more »

New symptoms of difficulty swallowing or a feeling like food is getting stuck in your throat can be worrying. Swallowing is often a process that people do instinctively and without thinking. You want to know why and how to fix it. You may also wonder if difficulty swallowing is a sign of cancer. ...Read more »